#35 Can Biomea Change the World with Irreversible Drugs and Covalent Bonds? Thomas Butler, CEO - Biomea Fusion

BioTech IQ

English - January 04, 2022 20:00 - 1 hour - 44.5 MB - ★★★★★ - 9 ratings
Life Sciences Science Business Investing Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: #33 Reducing friction at Clinical Trial Start-Up - Sam Searcy, CEO of CliniStart

Next Episode: #36 Can Shoreline Biosciences change the future of cell therapy through pluripotent stem cells?

Tom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep inactivation of target, and a greater therapeutic window.

https://biomeafusion.com/
https://thebiotechiqpodcast.com/podcast/

Support the show

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/